GlaxoSmithKline staff told not to publicise ineffectiveness of its drugBMJ 2004; 328 doi: https://doi.org/10.1136/bmj.328.7437.422-a (Published 19 February 2004) Cite this as: BMJ 2004;328:422
- David Spurgeon
CMAJ (the journal of the Canadian Medical Association) has published details of an internal document from the drug company GlaxoSmithKline that advised its staff to withhold the findings of a clinical trial in 1998 showing that the antidepressant paroxetine had no benefit in treating adolescents.
The association has publicised the document on its website in an early release of its Analysis column (www.cmaj.ca).
Last year, the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial